Amazonian N,N-DMT-containing brew; two US religious exemptions, most access abroad.
Ayahuasca is a plant preparation, not a molecule. The brew combines two plants that, taken separately, would not produce a psychedelic effect orally:
The MAOIs in the vine prevent the stomach from breaking down the DMT, allowing it to reach the brain via oral dosing. This is pharmacologically distinct from 5-MeO-DMT (a different molecule, vaporized rather than drunk) and from psilocybin (which does not require an MAOI).
Ceremonial ayahuasca is not a clinical procedure. A typical retreat session involves:
The most-cited trial is Palhano-Fontes et al. (2019), a randomized double-blind placebo-controlled trial in 29 patients with treatment-resistant depression. A single ayahuasca dose produced significantly greater MADRS score reductions than placebo at Day 7.4 The sample was small and the trial was single-site, so this should be read as a promising signal rather than a definitive answer.
Most ayahuasca research is observational — surveys of long-term ceremonial users and small open-label studies — rather than placebo-controlled. These generally report reductions in depressive, anxious, and substance-use symptoms, but the self-selection bias in retreat-goers is severe and the findings should not be interpreted as clinical evidence at the same level as ketamine or psilocybin trials.
Other important safety issues:
The active ingredient DMT is a Schedule I controlled substance — possession and distribution carry felony penalties. The Religious Freedom Restoration Act (RFRA) creates a narrow path for religious organizations to obtain DEA exemptions. The landmark case was Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006), in which the US Supreme Court ruled unanimously that the UDV could use ayahuasca sacramentally.1
As of 2026, four organizations are confirmed to have federal protection:
Several US cities have deprioritized enforcement of entheogens (Denver, Oakland, Santa Cruz, Ann Arbor, Seattle, Washington DC). These measures do not legalize ayahuasca and do not bind federal authorities.
Colorado’s Natural Medicine Health Act (Proposition 122, 2022) defined "natural medicine" to include DMT alongside psilocybin, psilocin, ibogaine, and mescaline. Through June 2026 only psilocybin and psilocin are authorized in the regulated program. The state Natural Medicine Advisory Board may recommend adding DMT (ayahuasca) after that date, though federal illegality would remain.
Legally, in the US: join one of the four confirmed exempt churches (UDV, Santo Daime branches, Iowaska Church of Healing, Church of Gaia). These are religious communities, not therapeutic retreat centers.
Abroad: Peru has the most developed legal framework — ayahuasca was declared national cultural heritage in 2008 — and centers there range from traditional Shipibo lineage operations to commercial retreats serving Western clients. Costa Rica, Brazil, and the Netherlands also host legal retreats. Quality varies enormously; medical screening, SSRI tapering, and on-site medical support should be considered non-negotiable.
What to avoid. Retreats that don’t require a detailed medical and medication history. Operators making clinical claims (depression cure, PTSD treatment) without any clinical infrastructure. US-based "ceremonies" without a formal DEA exemption.
Ayahuasca experiences are long, visually intense, and frequently bring up unresolved material. Dropping back into ordinary life without therapeutic support is, empirically, where most negative outcomes happen — not during the ceremony itself. A working relationship with a clinician trained in psychedelic integration before and after the retreat is strongly advised.